TELEFLEX INCORPORATED Reports 5.5% Increase in Revenues for Second Quarter of FY2023

August 25, 2023

☀️Earnings Overview

TELEFLEX INCORPORATED ($NYSE:TFX) reported total revenue of USD 743.3 million and net income of USD 111.3 million for the second quarter of FY2023, ending June 30 2023, representing a year-over-year increase of 5.5% in both figures.


GoodWhale has conducted an in-depth analysis of TELEFLEX INCORPORATED‘s wellbeing and its capability as an investment. The company was given a medium risk rating in terms of financial and business parameters. To give a more detailed insight into the company, GoodWhale has identified two risk warnings on its income sheet and balance sheet. To get a full understanding of the risks involved with investing in TELEFLEX INCORPORATED, it is recommended that potential investors register with GoodWhale to access the full risk assessment report. This report will provide an extensive overview of the company’s performance as well as an overall risk rating for the investment. With this information, investors can make more informed decisions about potential investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Teleflex Incorporated. More…

    Total Revenues Net Income Net Margin
    2.9k 368.57 13.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Teleflex Incorporated. More…

    Operations Investing Financing
    410.73 -242.6 -228.73
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Teleflex Incorporated. More…

    Total Assets Total Liabilities Book Value Per Share
    6.9k 2.68k 89.7
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Teleflex Incorporated are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    4.7% 5.1% 18.0%
    FCF Margin ROE ROA
    11.2% 7.8% 4.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    Teleflex Inc., a leading global provider of medical technologies, offers a broad range of products and services for use in critical care and surgery. The company’s products are used by hospitals and other healthcare facilities worldwide. Teleflex’s competitors include Delta Asia International Corp, Meihua International Medical Technologies Co Ltd, and Shanghai Sanyou Medical Co Ltd.

    – Delta Asia International Corp ($TPEX:6762)

    Daiwa-Asia International Corp is a leading provider of financial services in Asia. The company offers a wide range of products and services, including banking, insurance, asset management, and securities brokerage. Daiwa-Asia has a strong presence in the region, with operations in Hong Kong, Singapore, Taiwan, China, and Japan. The company is listed on the Tokyo Stock Exchange and has a market capitalization of 5.54 billion as of 2022. Daiwa-Asia reported a return on equity of 11.54% for the year ended March 31, 2022.

    – Meihua International Medical Technologies Co Ltd ($NASDAQ:MHUA)

    Meihua International Medical Technologies Co Ltd is a Chinese medical technology company. It has a market cap of 191.52M as of 2022 and a Return on Equity of 16.31%. The company develops, manufactures, and sells medical devices and equipment. Its products include stents, catheters, and other cardiovascular products.

    – Shanghai Sanyou Medical Co Ltd ($SHSE:688085)

    Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 7.06B as of 2022 and a Return on Equity of 8.19%. The company specializes in the manufacture and sale of medical equipment and supplies. It is headquartered in Shanghai, China.


    TELEFLEX INCORPORATED‘s second quarter of FY2023 saw significant growth in both total revenue and net income, with increases of 5.5% and 5.5% respectively compared to the same quarter in the previous year. Nevertheless, the stock price dropped on the day the results were announced. Investors should take this into consideration when making decisions on TELEFLEX, as it could indicate market forces at play that are not entirely in line with the reported financial results. However, the overall positive performance of the company in terms of revenue and income should be taken as a good sign for the future of TELEFLEX INCORPORATED’s stock.

    Recent Posts

    Leave a Comment